In recent years, a popular view of the pathogenesis of autoimmune disorders has been that B-cell derived events are ancillary to a basic breakdown in T-cell tolerance, and that although autoantibodies are present, the effector function of T cells is the fundamental pathological component.
However, the B-cell-depleting antibody rituximab — originally developed as a lymphoma therapy — has recently been shown to be effective in the treatment of rheumatoid arthritis, and has received regulatory approval for this indication.
This success, as well as indicating that removal of the B-cell component is beneficial in rheumatoid arthritis, has ushered in a new era of exploration of the contribution of B cells to a range of immune disorders in general.
This review discusses the role of B cells in autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus and Sjogrens syndrome, and considers various therapeutic strategies involving modulation of B-cell function, including B-cell depletion, manipulation of B-cell survival, and targeting T-cell help, Toll-like receptors and Fc receptors.
The B-cell arm of the immune system has long been appreciated for its crucial role in pathogen resistance, but in the study of many autoimmune diseases, T cells have dominated the limelight for decades. However, the development of the B-cell-depleting antibody rituximab as a lymphoma therapy has provided a tool to probe the contribution made by B cells in several immune disorders. Recently, the success of B-cell depletion with rituximab in the treatment of rheumatoid arthritis has stimulated investigation of its effects in several other immune disorders, and considerable interest in the potential of drugs that can modulate B-cell function for the treatment of such diseases in general. This article discusses the role of B cells in a range of autoimmune disorders, including rheumatoid arthritis and systemic lupus erythematosus, and analyses approaches to therapeutic B-cell manipulation.
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Edwards, J. C. et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350, 2572–2581 (2004).
Edwards, J. C. & Cambridge, G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nature Rev. Immunol. 6, 394–403 (2006).
St Clair, E. W. & Tedder, T. F. New prospects for autoimmune disease therapy: B cells on deathwatch. Arthritis Rheum. 54, 1–9 (2006).
Martin, F. & Chan, A. C. B cell immunobiology in disease: evolving concepts from the clinic. Annu. Rev. Immunol. 24, 467–496 (2006).
Baumgarth, N., Tung, J. W. & Herzenberg, L. A. Inherent specificities in natural antibodies: a key to immune defense against pathogen invasion. Springer Semin. Immunopathol. 26, 347–362 (2005).
Haas, K. M., Poe, J. C., Steeber, D. A. & Tedder, T. F. B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae. Immunity 23, 7–18 (2005).
Milner, E. C., Anolik, J., Cappione, A. & Sanz, I. Human innate B cells: a link between host defense and autoimmunity? Springer Semin. Immunopathol. 26, 433–452 (2005).
Goodnow, C. C., Sprent, J., Fazekas de St Groth, B. & Vinuesa, C. G. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 435, 590–597 (2005).
Lopes-Carvalho, T. & Kearney, J. F. Marginal zone B cell physiology and disease. Curr. Dir. Autoimmun. 8, 91–123 (2005).
Bendelac, A., Bonneville, M. & Kearney, J. F. Autoreactivity by design: innate B and T lymphocytes. Nature Rev. Immunol. 1, 177–186 (2001).
McHeyzer-Williams, L. J. & McHeyzer-Williams, M. G. Antigen-specific memory B cell development. Annu. Rev. Immunol. 23, 487–513 (2005).
Shapiro-Shelef, M. & Calame, K. Regulation of plasma-cell development. Nature Rev. Immunol. 5, 230–242 (2005).
MacLennan, I. C. et al. Extrafollicular antibody responses. Immunol. Rev. 194, 8–18 (2003).
Manser, T. Textbook germinal centers? J. Immunol. 172, 3369–3375 (2004).
Kunkel, E. J. & Butcher, E. C. Plasma-cell homing. Nature Rev. Immunol. 3, 822–829 (2003).
Martin, F. & Chan, A. C. Pathogenic roles of B cells in human autoimmunity; insights from the clinic. Immunity 20, 517–527 (2004).
Lund, F. E., Garvy, B. A., Randall, T. D. & Harris, D. P. Regulatory roles for cytokine-producing B cells in infection and autoimmune disease. Curr. Dir. Autoimmun. 8, 25–54 (2005).
Harris, D. P., Goodrich, S., Gerth, A. J., Peng, S. L. & Lund, F. E. Regulation of IFN-γ production by B effector 1 cells: essential roles for T-bet and the IFN-γ receptor. J. Immunol. 174, 6781–6790 (2005).
Harris, D. P., Goodrich, S., Mohrs, K., Mohrs, M. & Lund, F. E. Cutting edge: the development of IL-4-producing B Cells (B effector 2 cells) is controlled by IL-4, IL-4 receptor-α, and Th2 cells. J. Immunol. 175, 7103–7137 (2005).
Gommerman, J. L. & Browning, J. L. Lymphotoxin/light, lymphoid microenvironments and autoimmune disease. Nature Rev. Immunol. 3, 642–655 (2003).
Braun, A., Takemura, S., Vallejo, A. N., Goronzy, J. J. & Weyand, C. M. Lymphotoxin β-mediated stimulation of synoviocytes in rheumatoid arthritis. Arthritis Rheum. 50, 2140–2150 (2004).
Drayton, D. L., Liao, S., Mounzer, R. H. & Ruddle, N. H. Lymphoid organ development: from ontogeny to neogenesis. Nature Immunol. 7, 344–353 (2006).
Aloisi, F. & Pujol-Borrell, R. Lymphoid neogenesis in chronic inflammatory diseases. Nature Rev. Immunol. 6, 205–217 (2006).
Scofield, R. H. Autoantibodies as predictors of disease. Lancet 363, 1544–1546 (2004).
Arbuckle, M. R. et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349, 1526–1533 (2003).
McClain, M. T. et al. The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum. 50, 1226–1232 (2004).
Gianani, R. & Eisenbarth, G. S. The stages of type 1A diabetes: 2005. Immunol. Rev. 204, 232–249 (2005).
Samuels, J., Ng, Y. S., Coupillaud, C., Paget, D. & Meffre, E. Impaired early B cell tolerance in patients with rheumatoid arthritis. J. Exp. Med. 201, 1659–1667 (2005).
Burkhardt, H. et al. Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. Eur. J. Immunol. 35, 1643–1652 (2005).
Rantapaa-Dahlqvist, S. et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 48, 2741–2749 (2003).
Nielen, M. M. et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 50, 380–386 (2004).
Berger, T. et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N. Engl. J. Med. 349, 139–145 (2003).
Melanitou, E., Devendra, D., Liu, E., Miao, D. & Eisenbarth, G. S. Early and quantal (by litter) expression of insulin autoantibodies in the nonobese diabetic mice predict early diabetes onset. J. Immunol. 173, 6603–6610 (2004).
Lee, L. A. Transient autoimmunity related to maternal autoantibodies: neonatal lupus. Autoimmun. Rev. 4, 207–213 (2005).
Vincent, A. et al. Antibodies in myasthenia gravis and related disorders. Ann. NY Acad. Sci. 998, 324–335 (2003).
Svensson, J. et al. Thyroid autoantibodies in cord blood sera from children and adolescents with autoimmune thyroiditis. Thyroid 16, 79–83 (2006).
Greeley, S. A. et al. Elimination of maternally transmitted autoantibodies prevents diabetes in nonobese diabetic mice. Nature Med. 8, 399–402 (2002).
Eisenberg, R. Do autoantigens define autoimmunity or vice versa? Eur. J. Immunol. 35, 367–370 (2005).
Lim, E. T. et al. Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult. Scler. 11, 492–494 (2005).
Wipke, B. T., Wang, Z., Nagengast, W., Reichert, D. E. & Allen, P. M. Staging the initiation of autoantibody-induced arthritis: a critical role for immune complexes. J. Immunol. 172, 7694–7702 (2004).
Wong, F. S. et al. Investigation of the role of B-cells in type 1 diabetes in the NOD mouse. Diabetes 53, 2581–2587 (2004).
Wardemann, H. et al. Predominant autoantibody production by early human B cell precursors. Science 301, 1374–1377 (2003).
Yurasov, S. et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J. Exp. Med. 201, 703–711 (2005).
Oldstone, M. B. Molecular mimicry, microbial infection, and autoimmune disease: evolution of the concept. Curr. Top. Microbiol. Immunol. 296, 1–17 (2005).
McClain, M. T. et al. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nature Med. 11, 85–89 (2005).
Omdal, R. et al. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur. J. Neurol. 12, 392–398 (2005).
Chan, O. T., Madaio, M. P. & Shlomchik, M. J. The central and multiple roles of B cells in lupus pathogenesis. Immunol. Rev. 169, 107–121 (1999).
Shlomchik, M. J., Craft, J. E. & Mamula, M. J. From T to B and back again: positive feedback in systemic autoimmune disease. Nature Rev. Immunol. 1, 147–153 (2001).
Novobrantseva, T. I. et al. Attenuated liver fibrosis in the absence of B cells. J. Clin. Invest. 115, 3072–3082 (2005).
O'Neill, S. K. et al. Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis. J. Immunol. 174, 3781–3788 (2005).
Chan, O. T., Hannum, L. G., Haberman, A. M., Madaio, M. P. & Shlomchik, M. J. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J. Exp. Med. 189, 1639–1648 (1999).
Liu, C. C., Manzi, S. & Ahearn, J. M. Biomarkers for systemic lupus erythematosus: a review and perspective. Curr. Opin. Rheumatol. 17, 543–549 (2005).
Croker, J. A. & Kimberly, R. P. SLE: challenges and candidates in human disease. Trends Immunol. 26, 580–586 (2005).
Sfikakis, P. P., Boletis, J. N. & Tsokos, G. C. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr. Opin. Rheumatol. 17, 550–557 (2005).
Weyand, C. M., Seyler, T. M. & Goronzy, J. J. B cells in rheumatoid synovitis. Arthritis Res. Ther. 7 (Suppl. 3), S9–S12 (2005).
van Dinther-Janssen, A. C., Pals, S. T., Scheper, R., Breedveld, F. & Meijer, C. J. Dendritic cells and high endothelial venules in the rheumatoid synovial membrane. J. Rheumatol. 17, 11–17 (1990).
Manzo, A. et al. Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. Eur. J. Immunol. 35, 1347–1359 (2005).
Barone, F. et al. Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjogren's syndrome. Arthritis Rheum. 52, 1773–1784 (2005).
Salomonsson, S. et al. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjogren's syndrome. Arthritis Rheum. 48, 3187–3201 (2003).
Colvin, R. B. & Smith, R. N. Antibody-mediated organ-allograft rejection. Nature Rev. Immunol. 5, 807–817 (2005).
Krukemeyer, M. G. et al. Description of B lymphocytes and plasma cells, complement, and chemokines/receptors in acute liver allograft rejection. Transplantation 78, 65–70 (2004).
Moeller, J. et al. Molecular case report: IgVH analysis in acute humoral and cellular liver allograft rejection suggests a selected accumulation of effector B cells and plasma cells. Virchows Arch. 446, 325–332 (2005).
Vongwiwatana, A., Tasanarong, A., Hidalgo, L. G. & Halloran, P. F. The role of B cells and alloantibody in the host response to human organ allografts. Immunol. Rev. 196, 197–218 (2003).
Sospedra, M. & Martin, R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23, 683–747 (2005).
Uccelli, A., Aloisi, F. & Pistoia, V. Unveiling the enigma of the CNS as a B-cell fostering environment. Trends Immunol. 26, 254–259 (2005).
Pender, M. P. The pathogenesis of primary progressive multiple sclerosis: antibody-mediated attack and no repair? J. Clin. Neurosci. 11, 689–692 (2004).
Corcione, A. et al. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc. Natl Acad. Sci. USA 101, 11064–11069 (2004).
Krumbholz, M. et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J. Exp. Med. 201, 195–200 (2005).
Liu, J. et al. Genomic view of systemic autoimmunity in MRLlpr mice. Genes Immun 7, 156–168 (2006).
Hasegawa, M., Fujimoto, M., Takehara, K. & Sato, S. Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis. J. Dermatol. Sci. 39, 1–7 (2005).
Takehara, K. & Sato, S. Localized scleroderma is an autoimmune disorder. Rheumatology (Oxford) 44, 274–279 (2005).
Matsushita, T. et al. Elevated serum BAFF levels in patients with systemic sclerosis: Enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum. 54, 192–201 (2006).
Jindal, S. K. & Agarwal, R. Autoimmunity and interstitial lung disease. Curr. Opin. Pulm. Med. 11, 438–446 (2005).
Carroll, M. C. & Holers, V. M. Innate autoimmunity. Adv. Immunol. 86, 137–157 (2005).
Burne-Taney, M. J., Yokota-Ikeda, N. & Rabb, H. Effects of combined T- and B-cell deficiency on murine ischemia reperfusion injury. Am. J. Transplant. 5, 1186–1193 (2005).
Kotlan, B. et al. Novel ganglioside antigen identified by B cells in human medullary breast carcinomas: the proof of principle concerning the tumor-infiltrating B lymphocytes. J. Immunol. 175, 2278–2285 (2005).
de Visser, K. E., Korets, L. V. & Coussens, L. M. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7, 411–423 (2005).
Guillem, E. B. & Sampsel, J. W. Immune-promoted tumor cell invasion and metastasis. New considerations in cancer therapy. Adv. Exp. Med. Biol. 532, 153–173 (2003).
Looney, R. J., Anolik, J. & Sanz, I. Treatment of SLE with anti-CD20 monoclonal antibody. Curr. Dir. Autoimmun. 8, 193–205 (2005).
Keystone, E. C. B cells in rheumatoid arthritis: from hypothesis to the clinic. Rheumatology (Oxford) 44, (Suppl. 2), ii8–ii12 (2005).
Cohen, S. B. B-cell depletion for rheumatic diseases: where are we? MedGenMed 7, 72 (2005).
Panayi, G. S. B cell-directed therapy in rheumatoid arthritis — clinical experience. J. Rheumatol. Suppl 73, 19–24; discussion 29–30 (2005).
Edwards, J. C. & Cambridge, G. Prospects for B-cell-targeted therapy in autoimmune disease. Rheumatology (Oxford) 44, 151–156 (2005).
Pijpe, J. et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum. 52, 2740–2750 (2005).
Keogh, K. A. et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am. J. Respir. Crit. Care Med. 173, 180–187 (2006).
Leandro, M. J., Cambridge, G., Edwards, J. C., Ehrenstein, M. R. & Isenberg, D. A. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 44, 1542–1545 (2005).
Silverman, G. J. Anti-CD20 therapy in systemic lupus erythematosus: a step closer to the clinic. Arthritis Rheum. 52, 371–377 (2005).
Chambers, S. A. & Isenberg, D. Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases. Lupus 14, 210–214 (2005).
Vugmeyster, Y. et al. Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis. J. Immunother. 28, 212–219 (2005).
Hamaguchi, Y., Xiu, Y., Komura, K., Nimmerjahn, F. & Tedder, T. F. Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy. J. Exp. Med. 203, 743–753 (2006).
Uchida, J. et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199, 1659–1669 (2004).
Cartron, G., Watier, H., Golay, J. & Solal-Celigny, P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 104, 2635–2642 (2004).
Gong, Q. et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. 174, 817–826 (2005).
Janas, E., Priest, R., Wilde, J. I., White, J. H. & Malhotra, R. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin. Exp. Immunol. 139, 439–446 (2005).
Anolik, J. H. et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 50, 3580–3590 (2004).
Hamaguchi, Y. et al. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J. Immunol. 174, 4389–99 (2005).
Schroder, C. et al. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl. Immunol. 12, 19–28 (2003).
Leandro, M. J., Cambridge, G., Ehrenstein, M. R. & Edwards, J. C. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 54, 613–620 (2006).
Cambridge, G. et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 48, 2146–2154 (2003).
Cambridge, G. et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 54, 723–732 (2006).
Rouziere, A. S., Kneitz, C., Palanichamy, A., Dorner, T. & Tony, H. P. Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody. Arthritis Res. Ther. 7, R714–R724 (2005).
Sato, T. et al. Aberrant B1 cell migration into the thymus results in activation of CD4 T cells through its potent antigen-presenting activity in the development of murine lupus. Eur. J. Immunol. 34, 3346–3358 (2004).
Hoyer, B. F. et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J. Exp. Med. 199, 1577–1584 (2004).
Hoyer, B. F., Manz, R. A., Radbruch, A. & Hiepe, F. Long-lived plasma cells and their contribution to autoimmunity. Ann. NY Acad. Sci. 1050, 124–133 (2005).
Openshaw, H. et al. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol. Blood. Marrow. Transplant. 6, 563–575 (2000).
Qin, Y. et al. Intrathecal B-cell clonal expansion, an early sign of humoral immunity, in the cerebrospinal fluid of patients with clinically isolated syndrome suggestive of multiple sclerosis. Lab. Invest. 83, 1081–1088 (2003).
Saiz, A. et al. MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS. Neurology 56, 1084–1089 (2001).
Treon, S. P. et al. Polymorphisms in FcγRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J. Clin. Oncol. 23, 474–481 (2005).
Anolik, J. H. et al. The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 48, 455–459 (2003).
Cartron, G. et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99, 754–758 (2002).
Weng, W. K. & Levy, R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21, 3940–3947 (2003).
Tedder, T. F., Poe, J. C. & Haas, K. M. CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv. Immunol. 88, 1–50 (2005).
Yazawa, N., Hamaguchi, Y., Poe, J. C. & Tedder, T. F. Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc. Natl Acad. Sci. USA 102, 15178–15183 (2005).
Dillon, S. R., Gross, J. A., Ansell, S. M. & Novak, A. J. An APRIL to remember: novel TNF ligands as therapeutic targets. Nature Rev. Drug Discov. 5, 235–246 (2006).
Crowley, J. E., Treml, L. S., Stadanlick, J. E., Carpenter, E. & Cancro, M. P. Homeostatic niche specification among naive and activated B cells: a growing role for the BLyS family of receptors and ligands. Semin. Immunol. 17, 193–199 (2005).
Kalled, S. L. The role of BAFF in immune function and implications for autoimmunity. Immunol. Rev. 204, 43–54 (2005).
Mackay, F., Sierro, F., Grey, S. T. & Gordon, T. P. The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr. Dir. Autoimmun. 8, 243–265 (2005).
Ng, L. G., Mackay, C. R. & Mackay, F. The BAFF/APRIL system: life beyond B lymphocytes. Mol. Immunol. 42, 763–772 (2005).
Vugmeyster, Y. et al. A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys. Am. J. Pathol. 168, 476–489 (2006).
Halpern, W. G. et al. Chronic administration of belimumab, a blys antagonist, decreases tissue and peripheral blood b-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic and toxicologic effects. Toxicol Sci 91, 586–599 (2006).
Ellyard, J. I., Avery, D. T., Mackay, C. R. & Tangye, S. G. Contribution of stromal cells to the migration, function and retention of plasma cells in human spleen: potential roles of CXCL12, IL-6 and CD54. Eur. J. Immunol. 35, 699–708 (2005).
Castigli, E. et al. TACI and BAFF-R mediate isotype switching in B cells. J. Exp. Med. 201, 35–39 (2005).
Castigli, E. et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nature Genet. 37, 829–834 (2005).
Salzer, U. et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nature Genet. 37, 820–828 (2005).
Salzer, U. & Grimbacher, B. TACItly changing tunes: farewell to a yin and yang of BAFF receptor and TACI in humoral immunity? New genetic defects in common variable immunodeficiency. Curr. Opin. Allergy Clin. Immunol. 5, 496–503 (2005).
De Vos, J. et al. Microarray-based understanding of normal and malignant plasma cells. Immunol. Rev. 210, 86–104 (2006).
Haberman, A. M. & Shlomchik, M. J. Reassessing the function of immune-complex retention by follicular dendritic cells. Nature Rev. Immunol. 3, 757–764 (2003).
Mao, C. et al. T cell-independent somatic hypermutation in murine B cells with an immature phenotype. Immunity 20, 133–144 (2004).
Quezada, S. A., Jarvinen, L. Z., Lind, E. F. & Noelle, R. J. CD40/CD154 interactions at the interface of tolerance and immunity. Annu. Rev. Immunol. 22, 307–328 (2004).
Yazdany, J. & Davis, J. The role of CD40 ligand in systemic lupus erythematosus. Lupus 13, 377–380 (2004).
Boumpas, D. T. et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 48, 719–727 (2003).
Huang, W. et al. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum. 46, 1554–1562 (2002).
Danese, S. & Fiocchi, C. Platelet activation and the CD40/CD40 ligand pathway: mechanisms and implications for human disease. Crit. Rev. Immunol. 25, 103–121 (2005).
Wang, Y. & Carter, R. H. CD19 regulates B cell maturation, proliferation, and positive selection in the FDC zone of murine splenic germinal centers. Immunity 22, 749–761 (2005).
Davidson, A., Diamond, B., Wofsy, D. & Daikh, D. Block and tackle: CTLA4Ig takes on lupus. Lupus 14, 197–203 (2005).
Watts, T. H. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23, 23–68 (2005).
Hutloff, A. et al. Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. Arthritis Rheum. 50, 3211–3220 (2004).
Warnatz, K. et al. Human ICOS deficiency abrogates the germinal center reaction and provides a monogenic model for common variable immunodeficiency. Blood 107, 3045–3052 (2006).
Tackey, E., Lipsky, P. E. & Illei, G. G. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 13, 339–343 (2004).
Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M. & Stockinger, B. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24, 179–189 (2006).
Mihara, M., Nishimoto, N. & Ohsugi, Y. The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opin. Biol. Ther. 5, 683–690 (2005).
Yokota, S. et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 52, 818–825 (2005).
Kishimoto, T. Interleukin-6: from basic science to medicine — 40 years in immunology. Annu. Rev. Immunol. 23, 1–21 (2005).
Nishimoto, N. et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106, 2627–2632 (2005).
Ozaki, K. et al. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J. Immunol. 173, 5361–5371 (2004).
Baechler, E. C. et al. Gene expression profiling in human autoimmunity. Immunol. Rev. 210, 120–137 (2006).
Banchereau, J., Pascual, V. & Palucka, A. K. Autoimmunity through cytokine-induced dendritic cell activation. Immunity 20, 539–550 (2004).
Pasare, C. & Medzhitov, R. Control of B-cell responses by Toll-like receptors. Nature 438, 364–648 (2005).
Barrat, F. J. et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202, 1131–1139 (2005).
Lau, C. M. et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J. Exp. Med. 202, 1171–1177 (2005).
Vollmer, J. et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J. Exp. Med. 202, 1575–1585 (2005).
Rifkin, I. R., Leadbetter, E. A., Busconi, L., Viglianti, G. & Marshak-Rothstein, A. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol. Rev. 204, 27–42 (2005).
Christensen, S. R. et al. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J. Exp. Med. 202, 321–331 (2005).
Means, T. K. & Luster, A. D. Toll-like receptor activation in the pathogenesis of systemic lupus erythematosus. Ann. NY Acad. Sci. 1062, 242–251 (2005).
Theofilopoulos, A. N., Baccala, R., Beutler, B. & Kono, D. H. Type I interferons (α/β) in immunity and autoimmunity. Annu. Rev. Immunol. 23, 307–336 (2005).
Nimmerjahn, F. & Ravetch, J. V. Fcγ receptors: old friends and new family members. Immunity 24, 19–28 (2006).
Nakamura, A., Akiyama, K. & Takai, T. Fc receptor targeting in the treatment of allergy, autoimmune diseases and cancer. Expert Opin. Ther. Targets 9, 169–190 (2005).
Fukuyama, H., Nimmerjahn, F. & Ravetch, J. V. The inhibitory Fcγ receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nature Immunol. 6, 99–106 (2005).
McGaha, T. L., Sorrentino, B. & Ravetch, J. V. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science 307, 590–593 (2005).
Floto, R. A. et al. Loss of function of a lupus-associated FcγRIIb polymorphism through exclusion from lipid rafts. Nature Med. 11, 1056–1058 (2005).
Kono, H. et al. FcγRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. Hum. Mol. Genet. 14, 2881–2892 (2005).
Blank, M. C. et al. Decreased transcription of the human FCGR2B gene mediated by the-343 G/C promoter polymorphism and association with systemic lupus erythematosus. Hum. Genet. 117, 220–227 (2005).
Sturfelt, G. & Truedsson, L. Complement and its breakdown products in SLE. Rheumatology (Oxford) 44, 1227–1232 (2005).
Lemieux, R., Bazin, R. & Neron, S. Therapeutic intravenous immunoglobulins. Mol. Immunol. 42, 839–848 (2005).
Vaccaro, C., Zhou, J., Ober, R. J. & Ward, E. S. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nature Biotechnol. 23, 1283–1288 (2005).
Iglesias, J., D'Agati, V. D. & Levine, J. S. Acute glomerulonephritis occurring during immunoadsorption with staphylococcal protein A column (Prosorba). Nephrol. Dial. Transplant. 19, 3155–3159 (2004).
Zandman-Goddard, G. & Shoenfeld, Y. Novel approaches to therapy for SLE. Clin. Rev. Allergy Immunol. 25, 105–112 (2003).
Jonkers, R. E. & van der Zee, J. S. Anti-IgE and other new immunomodulation-based therapies for allergic asthma. Neth. J. Med. 63, 121–128 (2005).
Holgate, S. T., Djukanovic, R., Casale, T. & Bousquet, J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin. Exp. Allergy 35, 408–416 (2005).
Zhang, K. et al. Inhibition of allergen-specific IgE reactivity by a human Ig Fcγ–Fcɛ bifunctional fusion protein. J. Allergy Clin. Immunol. 114, 321–327 (2004).
Kimby, E. Tolerability and safety of rituximab (MabThera). Cancer Treat. Rev. 31, 456–473 (2005).
Manz, R. A., Hauser, A. E., Hiepe, F. & Radbruch, A. Maintenance of serum antibody levels. Annu. Rev. Immunol. 23, 367–386 (2005).
Merrill, J. T., Erkan, D. & Buyon, J. P. Challenges in bringing the bench to bedside in drug development for SLE. Nature Rev. Drug Discov. 3, 1036–1046 (2004).
The author would like to thank M. Kehry, E. Notidis, A. Ranger, E. Beckman, S. Kalled and L. Burkly for helpful discussions and critical reading.
J.B. is employed at Biogen Idec, which, along with Genentech and Roche are developing and selling Rituximab for the treatment of autoimmune disease. Likewise, Biogen Idec and Genentech are jointly developing BAFF receptor blockers for similar indications. A favourable article could be seen as advertising.
- Rheumatoid factors (Rf)
Antibodies capable of recognizing soluble immunoglobulins. These antibodies represent a form of autoreactivity and are prevalent in rheumatoid arthritis and SLE.
- Natural antibodies
Typically IgM antibodies formed early in development. These antibodies are produced by B1 cells (in mice) and do not display extensive hypermutation. They often have a low affinity for structures on the surfaces of bacteria and often can recognize multiple antigens — that is, they are polyreactive.
- Plasma cells
Terminally differentiated B cells essentially dedicated to massive secretion of immunoglobulins. Short (2–3 days) and long-lived (∼0.5–1 year) versions exist; long-lived cells reside in the bone marrow and the short-lived cells remain in the splenic red pulp and the medullary cords of the lymph nodes. The gut compartment also has large numbers of plasma cells.
- Extrafollicular response
For 2–6 days following B-cell activation in the presence of T-cell help, B cells undergo rapid proliferation and differentiation, leading to a burst of plasmablasts. Foci containing these cells remain in the T-cell region of the secondary lymphoid tissues. The resultant plasmablasts reside in the red pulp or medullary cords of the lymph nodes and survive for about 2–3 days.
- Germinal-centre reaction
A collection of rapidly dividing B cells assembled on a scaffold of reticular cells. Within this nucleus, affinity maturation and class-switching events are optimized, and memory B cells and plasmablasts are generated.
- Fc receptors
A family of generally low-affinity receptors that bind the immunoglobulin Fc domain. Oligomerized immunoglobulin is required for effective binding, and so these receptors serve a pivotal role as one of the primary sensors of immune complex formation. The receptors come in activating and inhibitory versions, and the balance between these two functions determines whether there is a response to immune complexes.
An enzyme cascade triggered by IgG immune complexes, bound IgM, some mannose-containing substances or certain bacterial surfaces. Activation deposits covalently the protein C3b on the antigen or pathogen, thereby marking it for binding by the various complement receptors. In the case of a cell surface, complement activation triggers the assembly of the membrane attack complex that kills the cell by forming pores in membrane.
- Co-stimulatory molecules
A central dogma of immunology states that activation of T- or B-cell receptors alone is insufficient to initiate an immune response. Only when activation is accompanied by a second or third signal does cell activation ensue. The membrane receptors and ligands that provide the second and third signals are collectively referred to as co-stimulatory molecules.
- Lymphotoxin system
Within the TNF family, the lymphotoxin-α/βligand binds to the lymphotoxin-β receptor on a subset of specialized stromal or endothelial cells to maintain their differentiation status. Constitutive lymphotoxin-β receptor signalling is required to maintain various micro-environments such as the polarized B-cell follicles, follicular dendritic cells and high endothelial venules.
- Non-obese diabetic mice
(NOD mouse). A strain of autoimmune-prone mice that spontaneously develops diabetes due to an autoimmune attack on the pancreatic islet cells. This mouse serves as a common model for autoimmune disease and specifically human type I diabetes.
- Lymphoid neogenesis
Within chronically inflamed tissues, leukocytic infiltrates can organize into an ectopic structure that resembles a lymph node. Aggregates of T and B cells, macrophages and dendritic cells assemble and specialized 'high endothelial venules' develop, allowing for additional trafficking opportunities. In the most organized cases, T cells segregate spatially from B cells, and germinal-centre reactions form within the B-cell follicle.
- Antibody-dependent cellular cytotoxicity
(ADCC). Antibody-coated cells can be recognized by Fc receptors on natural killer cells and macrophages. Receptor engagement leads to direct killing of the coated cell by release of various agents.
- Complement-dependent cytotoxicity
(CDC). Complement components assemble on complexes between antibodies and antigen (immune complexes). The assembly culminates with formation of the membrane attack complex, which directly creates pores in the membrane surface and kills the cell.
- Affinity maturation
Somatic hypermutation results in altered antibodies and occurs efficiently in the germinal centre. Antibodies with higher affinity for the antigen are selected for as the response progresses.
About this article
Cite this article
Browning, J. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 5, 564–576 (2006). https://doi.org/10.1038/nrd2085
Nature Reviews Drug Discovery (2021)
CD20 positive CD8 T cells are a unique and transcriptionally-distinct subset of T cells with distinct transmigration properties
Scientific Reports (2021)
Pharmacokinetics and Safety of Intravenous and Subcutaneous Auto-injector Single-dose Belimumab in Healthy Chinese Volunteers: A phase 1, Randomized, Open-label Study
Rheumatology and Therapy (2021)
Nature Reviews Cardiology (2019)
Scientific Reports (2019)